Last reviewed 2026-04-20 · How we verify

TECHNETIUM TC 99M DISOFENIN

FDA-approved approved Small molecule Quality 2/100

TECHNETIUM TC 99M DISOFENIN is a drug. It is currently FDA-approved (first approved 1982).

Techneium TC 99m Disofenin is a marketed radiopharmaceutical agent with a key composition patent expiring in 2028. Its primary strength lies in its established market presence and long-standing use in diagnostic imaging. The primary risk is the potential increase in competition following the 2028 patent expiry.

At a glance

Generic name	TECHNETIUM TC 99M DISOFENIN
Modality	Small molecule
Phase	FDA-approved
First approval	1982

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Source	Used for
FDA label	Mechanism, indications, dosing, boxed warnings, drug interactions

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

TECHNETIUM TC 99M DISOFENIN CI brief — competitive landscape report
TECHNETIUM TC 99M DISOFENIN updates RSS · CI watch RSS

Frequently asked questions about TECHNETIUM TC 99M DISOFENIN

What is TECHNETIUM TC 99M DISOFENIN?

TECHNETIUM TC 99M DISOFENIN is a Small molecule drug.

When was TECHNETIUM TC 99M DISOFENIN approved?

TECHNETIUM TC 99M DISOFENIN was first approved on 1982.

What development phase is TECHNETIUM TC 99M DISOFENIN in?

TECHNETIUM TC 99M DISOFENIN is FDA-approved (marketed).